Consistent with the overall prognosis analysis above, the high MTHFD2 expression group was linked to a poor prognosis compared to the low MTHFD2 expression group, including the subgroup of Clinical stage: stage I, histologic grade: G2, tumor invasion(%)˂50, menopause status: post, residual tumor: R0, primary therapy outcome: CR, PD&SD&PR&CR, surgical approach: minimally invasive, surgical approach: open, radiation therapy: no, hormones therapy: no (Fig. 5A-L). The gene discussed is MTHFD2; the disease is neoplasm.